Osimertinib (Tagrisso) is currently being reviewed by the Cancer Treatments Subcommittee of PHARMAC (CaTSoP) to consider whether to fund Osimertinib to treat patients with EGFR T790 mutation positive non-small cell lung cancer (NSCLC).

Lung Foundation New Zealand has written to CaTSoP on behalf of patients & families affected by lung cancer, urging this committee to recommend Pharmac to reimburse Osimertinib in NZ.

Funding more effective treatments like Osimertinib will; help to reduce the health inequalities and inequity that is associated with lung cancer, it will give patients more precious time with their family, enable many to return to work and reduce hospitalisation costs…

2018 April – Lung Foundation NZ – Pharmac, Cancer Treatments Subcommittee of PTAC